Albany, NY -- (SBWIRE) -- 10/25/2019 -- Synovial Sarcoma Market Insights, Epidemiology and Market Forecast-2028

1. The United accounted for most synovial sarcoma incident cases in 7MM with 576 cases in 2017.
2. Among EU5, Germany has the highest number of synovial sarcoma incident cases accounting for 331cases in 2017.
3. The Total diagnosed synovial sarcoma incident cases in 7MM were 1777 in 2017, the United States account for highest diagnosed incident cases of synovial sarcoma. In 2017, the United States had 489 diagnosed synovial sarcoma incident cases in 2017.

(Albany, US) DelveInsight launched a new report on Synovial Sarcoma Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Synovial Sarcoma market report covers a descriptive overview and comprehensive insight of the Synovial Sarcoma epidemiology and Synovial Sarcoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Synovial Sarcoma market report provides insights on the current and emerging therapies.
3. Synovial Sarcoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Synovial Sarcoma market report offers an edge that will help in developing business strategies by understanding trends moulding and leading the Synovial Sarcoma market.

Request for sample pages
"There were 2091 synovial sarcoma incident cases in 7MM."

The Synovial Sarcoma market size in seven major markets was USD 59.43 Million in 2017. The United States accounts for the Synovial Sarcoma largest market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. Japan accounts for the lowest Synovial Sarcoma market size in 7 MM when compared to the US and EU5 countries (combined market) i.e., USD 7.30 Million in 2017.
Synovial sarcoma is a rare sarcoma driven by a translocation between SS18 and SSX 1, 2, or 4. The hybrid transcription factor SS18: SSX alters SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodelling and global methylation patterns that may allow for future therapeutic opportunities. Currently, surgery remains the cornerstone of treatment and the only curative locoregional approach of localized resectable STS including Synovial Sarcoma cases. While considering the overall disease management perspective, first-line treatment usually consists of wide margin surgery plus radiotherapy. However, the Synovial Sarcoma market forecast model is based entirely on pharmacological therapies and does not include any procedural or surgical methods. Therefore, chemotherapy forms the first line of defence to treat most metastatic sarcomas with Synovial Sarcoma being no exception.
The Synovial Sarcoma landscape market is speculated to change in the coming years owing to the launch of several Synovial Sarcoma upcoming therapies. A significant amount of research and developmental activities over the past several years have led to the gradual emergence of more effective and less toxic treatment modalities in Synovial Sarcoma patients.
The Synovial Sarcoma market size is mainly ruled by off-label chemotherapeutic agents. The upcoming therapies in each segment are estimated to change the Synovial Sarcoma market scenario. Overall, it can safely be assumed that the Synovial Sarcoma market is going to show a positive shift with a significant rise in revenue generation owing to increased awareness and a robust pipeline during the forecast period [2019-2028].

The launch of the emerging therapies is expected to significantly impact the Synovial Sarcoma treatment scenario in the upcoming years: -
Drugs covered
1. Tazemetostat
2. ADP-A2M4
3. Anlotinib (AL3818)
And many others

The key players in Synovial Sarcoma market are:
1. Epizyme
2. Adaptimmune
3. Advenchen Laboratories
And many others

Table of contents

1. Key Insights
2. Synovial Sarcoma Market Overview at a Glance
3. Synovial Sarcoma Disease Background and Overview
4. Synovial Sarcoma Epidemiology and Patient Population
5. Synovial Sarcoma Country Wise-Epidemiology
5.1. United States
5.2. EU5 Countries
5.3. Germany
5.4. France
5.5. Italy
5.6. Spain
5.7. United Kingdom
5.8. Japan
6. Guidelines for Synovial Sarcoma Treatment/ Management of Soft-Tissue Sarcoma
7. Unmet needs
8. Synovial Sarcoma Marketed Drugs
8.1. Yondelis (Trabectadin)
8.2. Pazopanib: Novartis
9. Synovial Sarcoma Emerging drugs
9.1. Tazemetostat: Epizyme, Inc.
9.2. ADP-A2M4: Adaptimmune
9.3. Anlotinib (AL3818): Advenchen Laboratories
10. Synovial Sarcoma 7 Major Market Analysis
11. The United States Market Outlook
11.1.United States Market Size
12. EU-5 Countries: Market Outlook
12.1.Germany
12.2. France
12.3. Italy
12.4. Spain
12.5. The United Kingdom
13. Japan: Market Outlook
13.1.Japan market Size
14. Market Drivers
15. Market Barriers
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight